Conclusions: BPA could be an effective treatment option for inoperable peripheral type CTEPH to achieve dramatic improvement of hemodynamic and outcome parameters. Further technical modification in attempting to reduce procedural complications will be required.
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Influence of balloon pulmonary angioplasty on prognosis in patients with chronic thrombo-embolic pulmonary hypertension Purpose: Balloon pulmonary angioplasty (BPA) has been reported to be effective and less invasive for the treatment of chronic thrombo-embolic pulmonary hypertension (CTEPH). This study sought to clarify the influence of BPA on prognosis in patients with CTEPH. Methods: Out of consecutive one hundred six patients with CTEPH, 58 patients underwent BPA (BPA group), 18 patients done pulmonary endarterectomy (PEA group), and 30 patients with only medical therapy (DRUG group) were compared with survival rate and mean pulmonary arterial pressure (PAP) at before and after each treatment. The endpoint was defined as cardiac death. Results: During a follow up of 36.7±31.1 months, the survival rate in DRUG group was significantly lower than in PEA and BPA groups (55% vs. 80% vs. 97%, p < 0.01, respectively). PAP before treatment in DRUG group was significantly lower than in PEA and BPA groups (38±7 mmHg vs. 50±9 mmHg vs. 45±10 mmHg, p < 0.01, respectively), and PAP after treatment was significantly higher (36±12 mmHg vs. 25±6 mmHg vs. 27±9 mmHg, p < 0.01, respectively). There were no significant differences in the degree of improvement of PAP between PEA and BPA groups. Conclusions: It is probably that efficacy of BPA for patients with CTEPH is equal to PEA in the medium and short term. 
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Arginase regulates formation and export of cardioprotective nitric oxide bioactivity from red blood cells
